BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+16.43%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$1.58B
AUM Growth
+$1.58B
(+34%)
Cap. Flow
+$233M
Cap. Flow
% of AUM
14.78%
Top 10 Holdings %
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11
Top Buys
| 1 |
Abbott
ABT
|
$14.5M |
| 2 |
Pacific Biosciences
PACB
|
$13.9M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$10.2M |
| 4 |
CareDx
CDNA
|
$9.72M |
| 5 |
Medtronic
MDT
|
$9.3M |
Top Sells
| 1 |
DexCom
DXCM
|
$28.5M |
| 2 |
Bausch Health
BHC
|
$3.02M |
| 3 |
Amgen
AMGN
|
$2.27M |
| 4 |
Gilead Sciences
GILD
|
$1.76M |
| 5 |
KTWO
K2M Group Holdings, Inc
KTWO
|
$1.67M |
Sector Composition
| 1 | Healthcare | 93.18% |
| 2 | Industrials | 1.09% |
| 3 | Technology | 0.34% |
| 4 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Elevance Health
ELV
$71.8B
| $61.4M | 3.9% | 224,188 +10,661 | +5% | +$2.92M |
|
2
Align Technology
ALGN
$10.3B
| $57.2M | 3.63% | 146,310 +15,252 | +12% | +$5.97M |
|
|
3
Abbott
ABT
$231B
| $56.2M | 3.57% | 766,710 +197,860 | +35% | +$14.5M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $54.2M | 3.44% | 606,000 +73,200 | +14% | +$6.55M |
|
5
Illumina
ILMN
$15.8B
| $54.2M | 3.44% | 147,707 +6,736 | +5% | +$2.47M |
|
6
Teladoc Health
TDOC
$1.37B
| $50.6M | 3.21% | 586,520 +16,410 | +3% | +$1.42M |
|
7
Intuitive Surgical
ISRG
$170B
| $50.4M | 3.2% | 87,868 +129 | +0.1% | +$74K |
|
|
8
Medtronic
MDT
$119B
| $48.8M | 3.1% | 496,446 +94,565 | +24% | +$9.3M |
|
9
Edwards Lifesciences
EW
$47.8B
| $44.1M | 2.8% | 253,333 +47,673 | +23% | +$8.3M |
|
10
Boston Scientific
BSX
$156B
| $37.7M | 2.39% | 978,929 +158,333 | +19% | +$6.1M |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $35.9M | 2.28% | 213,758 +48,825 | +30% | +$8.21M |
|
12
Cigna
CI
$80.3B
| $35.3M | 2.24% | 169,463 +43,229 | +34% | +$9M |
|
13
Humana
HUM
$36.5B
| $33.3M | 2.12% | 98,510 +11,660 | +13% | +$3.95M |
|
14
UnitedHealth
UNH
$281B
| $32.9M | 2.09% | 123,848 +27,119 | +28% | +$7.21M |
|
15
Centene
CNC
$14.3B
| $31.6M | 2% | 218,021 +54,774 | +34% | +$7.93M |
|
16
Becton Dickinson
BDX
$55.3B
| $27.5M | 1.75% | 105,413 +24,198 | +30% | +$6.32M |
|
17
Danaher
DHR
$147B
| $27.5M | 1.74% | 253,016 +34,551 | +16% | +$3.75M |
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $25.5M | 1.61% | 183,080 +19,350 | +12% | +$2.69M |
|
19
Stryker
SYK
$150B
| $25.1M | 1.59% | 141,380 +22,610 | +19% | +$4.02M |
|
20
Cencora
COR
$56.5B
| $22M | 1.4% | 238,853 | – | – |
|
21
Bristol-Myers Squibb
BMY
$96B
| $21.2M | 1.35% | 341,729 +80,880 | +31% | +$5.02M |
|
22
Viatris
VTRS
$12.3B
| $20.7M | 1.31% | 565,350 +63,000 | +13% | +$2.31M |
|
23
Baxter International
BAX
$12.7B
| $20.3M | 1.29% | 263,348 +53,348 | +25% | +$4.11M |
|
24
Supernus Pharmaceuticals
SUPN
$2.53B
| $19.5M | 1.23% | 386,500 +59,900 | +18% | +$3.02M |
|
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $19.2M | 1.22% | 219,891 +116,391 | +112% | +$10.2M |
|